同时组装非诺贝特和酮洛芬肽用于非酒精性脂肪性肝病（NAFLD）的双重靶向治疗。
Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD).
机构信息
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, P. R. China.
出版信息
Chem Commun (Camb). 2020 May 4;56(36):4922-4925. doi: 10.1039/d0cc00513d. Epub 2020 Apr 2.
PMID:32239031
Abstract
We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses.
摘要
我们开发了一种基于非诺贝特和酮洛芬的共组装纳米系统，巧妙地利用了它们的同时苯甲酮相互作用，极大地提高了非诺贝特的生物利用度，并通过减少肝脂质积累和炎症反应发挥双重靶向治疗非酒精性脂肪性肝病（NAFLD）的作用。
Zotero 插件